ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors

Summary

An open, single-arm, multi-center Phase II clinical study of ENVAFOLIMAB single-agent treatment in patients with advanced solid tumors,to compare the overall response rate of TMB-high and TMB-Low,to determine the cut off value between TMB-high and TMB-Low of diagnosis device.Then,observe the efficacy of ENVAFOLIMAB uesd comfirmed TMB-H Value

Timeline

Start

2021-08-06

Primary completion

2027-08-30

Completion

2028-04-30

Drugs

Indications